Disease control with entrectinib was found to be active and durable in ROS1 fusion-positive NSCLC.
Future studies should target gene members of these pathways.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
The third-generation drug performed better than erlotinib or gefitinib, according to researchers.
NCI-MATCH trial identified additional patients who may benefit from nivolumab.
Repeat biopsies may be needed prior to patient inclusion in targeted-therapy trials.
Patients with multiple myeloma may want to avoid consumption of foods associated with Listeria.
The likelihood of unpublished results remains highest among terminated trials.
Concomitant use of inhibitors allowed for the manufacture of more potent T cells.